Cagrilintide & CagriSema: Phase 3 Weight-Loss Evidence Reviewed (2026)

Cagrilintide is a long-acting amylin analog that Novo Nordisk pairs with semaglutide in a once-weekly combination called CagriSema. The big question heading into 2026 is simple: does adding an amylin drug to a GLP-1 deliver more weight loss than the GLP-1 alone, and is the trade-off in side effects worth it? The Phase 3 REDEFINE program gives us real answers, and they are strong but messier than the early hype suggested.

What Cagrilintide Actually Is

Cagrilintide is a synthetic version of amylin, a hormone your pancreas releases alongside insulin every time you eat. Natural amylin breaks down in minutes. Cagrilintide is engineered to last about a week, so a single injection keeps working between doses.

Amylin and GLP-1 are different hormones that hit different brain circuits. That difference is the whole point. The theory: stack two appetite-control systems and you get more total effect than either alone. CagriSema is the fixed-dose product that does exactly that. It combines cagrilintide 2.4 mg with semaglutide 2.4 mg in one weekly shot.

A note on terms. "Cagrilintide" on its own is the amylin drug. "CagriSema" is the combo product (cagrilintide plus semaglutide). They are not the same thing, and the trial results for each are different. This review covers both.

How It Works in the Body

Amylin analogs like cagrilintide do three main things. They slow how fast your stomach empties, so food sits longer and you feel full. They act on the hindbrain and hypothalamus to dial down appetite signals. And they appear to reduce the "compensatory" hunger that often limits how much weight people keep off long-term.

Semaglutide, the GLP-1 half, works on partly overlapping but distinct receptors. It also slows gastric emptying and curbs appetite, plus it improves blood sugar control. Pairing the two is meant to attack appetite from two angles at once. The mechanism is plausible and supported by animal and early human data, but the real test is whether the combo beats the parts in large trials. It did, and we will get to the numbers.

If you want the GLP-1 side explained in depth, see our semaglutide mechanism of action research review.

Why Amylin Is Suddenly a Big Deal

For years, the obesity drug story was almost entirely about GLP-1. Amylin was the quiet hormone in the background. That changed because of a stubborn problem: people on GLP-1 drugs tend to hit a weight-loss plateau, and the body fights back with hunger signals that make it hard to keep losing.

Amylin appears to work on a different part of that defense system. Where GLP-1 mostly tells the brain "you are full right now," amylin seems to lower the body's defended weight set point over time and reduce the rebound hunger that stalls progress. That is the mechanistic argument for stacking the two. It is also why several drugmakers are now racing to develop their own amylin drugs. Cagrilintide is the most advanced of them in a combination product.

One older amylin drug, pramlintide, has been on the market for years for diabetes, but it has to be injected at every meal and never produced dramatic weight loss. Cagrilintide's once-weekly design is the real advance. It made amylin practical to combine with a once-weekly GLP-1, which is exactly what CagriSema is.

The Evidence: What the Trials Show

This is where most write-ups overstate things. Let me grade the evidence honestly, study by study.

Phase 2: The Early Signal (Strong but Small)

Two Phase 2 trials set the stage. A 2021 dose-finding trial in The Lancet tested cagrilintide alone in 706 adults with overweight or obesity. Over 26 weeks, the highest dose produced about 10.8% mean weight loss versus roughly 3.0% with placebo. That established cagrilintide as a real appetite drug on its own.

A 2023 Phase 2 trial in The Lancet tested the cagrilintide-plus-semaglutide combo in people with type 2 diabetes. At 32 weeks, the combo produced larger weight loss than either drug alone. Promising, but these were short, mid-size studies. Phase 2 tells you a drug is worth pursuing. It does not prove the real-world payoff. The grade here: solid proof-of-concept, not definitive.

Phase 3 REDEFINE 1: The Headline Trial (Strong, with a Catch)

REDEFINE 1 is the one that matters most. It enrolled 3,417 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes. Participants were randomly assigned to CagriSema, cagrilintide alone, semaglutide alone, or placebo, once weekly for 68 weeks. Results were published in The New England Journal of Medicine in 2025.

Here is the core result table.

Treatment (68 weeks)	Mean weight loss	Reached =25% loss
CagriSema 2.4/2.4 mg	22.7%	40.4%
Semaglutide 2.4 mg	16.1%	16.2%
Cagrilintide 2.4 mg	11.8%	6.0%
Placebo	2.3%	0.9%

The combo clearly beat each single drug. CagriSema's 22.7% topped semaglutide's 16.1% by more than six percentage points, and it crushed placebo. About 60% of CagriSema patients lost at least 20% of their body weight, and roughly 23% lost 30% or more. Those are large numbers.

So what is the catch? Novo Nordisk's leadership had publicly hoped for around 25% average weight loss. The 22.7% result fell short of that internal target. When the topline came out in December 2024, the stock dropped sharply because Wall Street had priced in a bigger number. There was also a dosing wrinkle: only about 57% of patients reached the highest CagriSema dose, because the flexible protocol let people stay lower if side effects bothered them. That suggests the "true" ceiling under ideal dosing might be higher, but we cannot prove it from this trial.

Bottom line on REDEFINE 1: the efficacy is real and strong by any clinical standard. The "disappointment" was about beating an expectation, not about whether the drug works. Honest grade: high-quality evidence of meaningful added benefit over semaglutide alone.

Phase 3 REDEFINE 2: The Diabetes Trial (Good, More Modest)

REDEFINE 2 tested CagriSema in 1,206 adults who had obesity or overweight plus type 2 diabetes, again over 68 weeks versus placebo. Weight loss was smaller here, which is expected: people with type 2 diabetes typically lose less weight on these drugs than people without it.

REDEFINE 2 (68 weeks)	CagriSema	Placebo
Mean weight loss	~15.7%	~3.1%
=10% weight loss	74.1%	9.1%
=15% weight loss	51.6%	1.5%
=20% weight loss	29.2%	0.2%

The 15.7% figure comes from the analysis that counts only people who stayed on treatment as prescribed; a broader "treatment policy" analysis that includes everyone showed closer to 13.7%. Either way, it beat placebo by a wide margin and improved blood sugar control. Honest grade: good evidence, with the realistic caveat that diabetes blunts the effect.

Newer Trials and What's Still Unknown

A 2026 Phase 3a trial called REDEFINE 5 tested the combo against semaglutide alone in adults in Japan and Taiwan, published in The Lancet Diabetes & Endocrinology. A REDEFINE 1 sub-analysis published in 2026 also reported that CagriSema lowered blood pressure. These add breadth, but the obesity story still rests mainly on REDEFINE 1 and 2.

What we still do not know: long-term durability past about 68 weeks, head-to-head data against tirzepatide or the triple-agonist retatrutide, and whether the higher-dose ceiling is real. Those gaps matter for anyone making decisions today.

What the Numbers Actually Mean in Practice

A 22.7% average weight loss is easy to read past, so it helps to ground it. For a person who weighs 220 pounds, that average works out to roughly 50 pounds lost over about 16 months. The semaglutide-alone arm, at 16.1%, would be closer to 35 pounds for the same person. The gap between those two is real and clinically meaningful: an extra 15 pounds is the kind of difference that moves blood pressure, blood sugar, and joint load.

But "average" hides a wide spread. Some people in the CagriSema arm lost over 30% of their body weight. Others lost much less. Weight-loss drugs are not one-size-fits-all, and trial averages are not a promise for any single person. The roughly 40% of CagriSema patients who reached 25% or more loss is a useful upper-range marker, while the people on the lower end remind you that response varies a lot.

The other practical point is the comparison baseline. REDEFINE 1 stacked CagriSema against the strongest single GLP-1 available, not against a weak comparator. Beating semaglutide by six points is a higher bar than beating placebo, and it is the result that actually justifies adding a second drug and a second set of side effects.

Dosing and How the Drug Is Started

CagriSema in the trials was given as a once-weekly subcutaneous injection. The dose was not started at full strength. Patients escalated gradually over weeks, the same approach used with semaglutide, because ramping up slowly is the single most effective way to limit nausea and vomiting.

That slow titration is why the "57% reached the top dose" detail is worth understanding rather than fearing. The trial used a flexible protocol: if a patient felt sick at a higher step, they could stay at a lower dose instead of pushing through. Nearly half chose to stay lower. That kept side effects tolerable, but it also means the headline 22.7% reflects a mix of people, many of whom never reached the maximum dose. Whether a more aggressive, fixed-escalation protocol would push average weight loss higher is an open and genuinely interesting question that future trials may answer.

For broader context on how injectable peptide protocols are dosed and escalated, see our how to start peptide therapy guide.

How It Compares to Other Options

CagriSema does not exist in a vacuum. Here is the honest competitive picture as of mid-2026.

Versus semaglutide (Wegovy) alone: CagriSema wins on weight loss (22.7% vs 16.1% in REDEFINE 1). The cost is more gastrointestinal side effects.
Versus tirzepatide (Zepbound/Mounjaro): No direct head-to-head trial exists. Tirzepatide's pivotal SURMOUNT-1 trial showed roughly 21% mean weight loss at its top dose over 72 weeks. The numbers are in the same neighborhood, so claims that CagriSema is clearly superior to tirzepatide are not yet supported by data. They have not been compared in the same study.
Versus retatrutide: Retatrutide is a triple agonist still in Phase 3 that has posted even higher early weight-loss figures, but it is further from market. See our tirzepatide vs retatrutide comparison for that race.

The cleaner framing: CagriSema looks like a top-tier option that adds the amylin mechanism. Whether it is the single best drug depends on head-to-head data that does not exist yet.

A word of caution about cross-trial comparisons. It is tempting to line up "22.7% for CagriSema" against "21% for tirzepatide" and crown a winner. That is bad science. Different trials enroll different patients, run for different lengths, and use different statistical methods to handle people who drop out. A two-point gap between two separate studies is well inside the noise. The only honest answer to "which is best" is that nobody has run the trial that would tell us, and anyone claiming certainty is selling something.

What is fair to say: CagriSema, tirzepatide, and retatrutide are all in a tier far above semaglutide-alone-era expectations. The obesity drug landscape in 2026 has several genuinely powerful options, which is good news for patients even if it frustrates anyone looking for one clear answer.

Safety and Side Effects

The side-effect profile is the trade-off you accept for the extra weight loss. It is mostly gastrointestinal and mostly manageable, but it is not trivial.

Side effect (REDEFINE 1)	CagriSema	Placebo
Any GI adverse event	79.6%	39.9%
Nausea	~55%	~12.6%
Constipation	~30.7%	~11.6%
Vomiting	~26.1%	~4.1%
Discontinued due to side effects	~6%	~3.7%

Most GI events were mild to moderate and faded over time as the body adjusted. The key reassurance: even though four out of five patients had some GI symptom, only about 6% quit the drug because of side effects. That tells you most people tolerated it well enough to keep going. Slow dose escalation is the standard way to limit nausea and vomiting.

These are the same risks that come with all GLP-1 and amylin drugs. Standard warnings for this drug class include pancreatitis, gallbladder problems, and a thyroid-tumor signal seen in rodents (the human relevance is unsettled). Anyone considering this class should review the broader peptide therapy side effects and risks.

Two things deserve a clearer look. First, the GI side effects are front-loaded. They are worst during dose escalation and ease as the body adapts, which is why the discontinuation rate stayed low despite high symptom rates. Second, rapid weight loss of this magnitude raises the same long-term questions that apply to every potent obesity drug: muscle loss alongside fat, the need for adequate protein and resistance exercise, and the strong likelihood that weight returns if the drug is stopped. These are management issues, not reasons to avoid the drug, but they are real and often glossed over in marketing.

On the positive side of the ledger, REDEFINE 1 also reported improvements beyond the scale: lower systolic blood pressure, smaller waist circumference, better lipid levels, and improved blood sugar, with the large majority of participants who had prediabetes returning to normal glucose levels. Those metabolic gains are part of why this drug class matters for health, not just appearance. A 2026 sub-analysis confirmed the blood-pressure benefit specifically.

Regulatory and Access Status

As of mid-2026, CagriSema is not yet FDA-approved. Novo Nordisk submitted its New Drug Application to the FDA in December 2025, with a review expected through 2026 and a possible approval in late 2026 or 2027. That means it is a prescription product in the pipeline, not something available at a pharmacy or, importantly, something that should be sold as a "research peptide." Cagrilintide and CagriSema sold by gray-market vendors are not the studied, quality-controlled product. For why that distinction matters, see our review of compounded GLP-1 peptides legal and safety status.

Who It's For (and Who Should Wait)

Based on the trial populations, CagriSema is being developed for adults with obesity, or overweight plus a weight-related condition, including those with type 2 diabetes. The strongest case is for someone who needs more weight loss than a single GLP-1 has delivered and who can tolerate GI side effects.

Who should wait or look elsewhere:

Anyone who wants an approved, pharmacy-available drug today. CagriSema is not there yet.
People with a history of pancreatitis, certain thyroid cancers, or severe GI disease should not start any drug in this class without specialist guidance.
Anyone tempted to buy "cagrilintide" from a research-chemical site. That is not the tested product, the dosing is unverified, and the safety data above does not apply to it.

The realistic move for most people in 2026 is to use an already-approved option (semaglutide or tirzepatide) with a doctor, and watch the CagriSema approval timeline.

The Honest Verdict

CagriSema is one of the most effective weight-loss combinations ever tested in Phase 3, with about 22.7% mean weight loss in people without diabetes. The evidence quality is high: large randomized trials, published in top journals, with the combo clearly beating its individual parts. The "miss" you may have read about was a missed business expectation, not a failed drug.

The honest caveats: it is not yet approved, it carries meaningful GI side effects, the top-dose ceiling is still uncertain, and there is no head-to-head data against tirzepatide or retatrutide. Strong drug, real evidence, but a few open questions that should keep anyone from declaring it the definitive winner just yet.

Frequently Asked Questions

Is CagriSema better than Wegovy (semaglutide)?

In the REDEFINE 1 trial, CagriSema produced more weight loss than semaglutide alone (22.7% vs 16.1% over 68 weeks). So on the head-to-head measure in that single trial, yes, it delivered more weight loss. The trade-off is more gastrointestinal side effects. "Better" also depends on tolerance, cost, and availability, and CagriSema is not yet approved.

Did CagriSema fail its Phase 3 trial?

No. It met its primary endpoints and beat placebo and both single drugs. The confusion comes from Novo Nordisk having hoped for around 25% average weight loss; the 22.7% result fell short of that target, which is why the stock dropped. Missing an internal expectation is not the same as the trial failing.

What is the difference between cagrilintide and CagriSema?

Cagrilintide is the amylin analog by itself, which produced about 11.8% weight loss alone in REDEFINE 1. CagriSema is the combination product that pairs cagrilintide 2.4 mg with semaglutide 2.4 mg in one weekly injection, which produced 22.7%. They are related but not interchangeable.

Is CagriSema FDA-approved or available now?

No. Novo Nordisk filed its New Drug Application with the FDA in December 2025. A decision is expected during 2026, with possible approval in late 2026 or 2027. It is not available by prescription yet, and any "cagrilintide" sold by research-chemical vendors is not the tested, quality-controlled product.

How bad are the side effects?

Mostly gastrointestinal: nausea (~55%), constipation, and vomiting were common in trials, but usually mild to moderate and they faded over time. Despite high rates of symptoms, only about 6% of patients stopped the drug because of side effects, which suggests most people tolerated it. Slow dose escalation helps reduce nausea.

This article is for educational purposes only and is not medical advice. Cagrilintide and CagriSema are investigational and not FDA-approved as of mid-2026. Talk to a licensed healthcare provider before starting or changing any medication.